Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals

Rilpivirine (RPV), the latest nonnucleoside reverse transcriptase inhibitor active against HIV-1, is prescribed in a standard dosage of 25 mg once a day in combination with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). The aim of this observational study was to characterize the RPV ph...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Aouri, Manel, Barcelo, Catalina, Guidi, Monia, Rotger, Margalida, Cavassini, Matthias, Hizrel, Cédric, Buclin, Thierry, Decosterd, Laurent A., Csajka, Chantal
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2016
Soggetti:
Antiviral Agents
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5192124/
https://ncbi.nlm.nih.gov/pubmed/27799217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00899-16
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi